@article{1881a33a6dac49b2b27637f71db6e310,
title = "The role of stewardship in addressing Antibacterial resistance: Stewardship and infection control committee of the Antibacterial Resistance Leadership Group",
abstract = "Antibacterial resistance is increasing globally and has been recognized as a major public health threat. Antibacterial stewardship is the coordinated effort to improve the appropriate use of antibiotics with the aim to decrease selective pressure for multidrug-resistant organisms in order to preserve the utility of antibacterial agents. This article describes the activities of the Antibacterial Resistance Leadership Group (ARLG) in the area of antibacterial stewardship. To date, the ARLG has focused intensely on development of rapid diagnostic tests, which (when coupled with educational and institutional initiatives) will enable the robust stewardship that is needed to address the current crisis of antibacterial resistance. In addition to exploring the effectiveness of stewardship techniques in community hospitals, the ARLG has also developed strategy trials to assess the feasibility of reducing antibacterial usage while preserving patient outcome.",
keywords = "Antibacterial resistance, Infection control, Stewardship",
author = "Anderson, {Deverick J.} and Jenkins, {Timothy C.} and Evans, {Scott R.} and Harris, {Anthony D.} and Weinstein, {Robert A.} and Tamma, {Pranita D.} and Han, {Jennifer H.} and Ritu Banerjee and Robin Patel and Theoklis Zaoutis and Ebbing Lautenbach",
note = "Funding Information: Financial support. This article was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH (award number UM1AI104681). Funding Information: Potential conflicts of interest. S. R. E. has received grants from NIAID/NIH and Fogarty International Center and personal fees from the American Statistical Association, Society for Clinical Trials, Drug Information Association, US Food and Drug Administration, NIH, City of Hope, Huntington{\textquoteright}s Study Group, IMMPACT, PPRECISE, Muscle Study Group, DeGruyter (Statistical Communications in Infectious Diseases), Takeda, Pfizer, Roche, Novartis, Merck, Achaogen, Auspex, Alcon, Chelsea, Mannkind, QRx Pharma, Genentech, Affymax, FzioMed, Amgen, GlaxoSmithKline, Sunovion, Boehringer-Ingelheim, Cubist, AstraZeneca, Teva, Repros, Dexcom, Zeiss, University of Rhode Island, New Jersey Medical School–Rutgers, University of Vermont, Osaka University, and the National Cerebral and Cardiovascular Center of Japan. P. D. T. has received research grants from Merck and Pfizer. R. P. has received grants from BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company; has served as a consultant for Curetis, Roche, Qvella, and Diaxonhit (monies are paid Publisher Copyright: {\textcopyright} The Author 2017. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",
year = "2017",
doi = "10.1093/cid/ciw830",
language = "English (US)",
volume = "64",
pages = "S36--S40",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
}